On this page
Cost-effectiveness analysis (CEA) compares costs to natural units of health gain like life years saved, while cost-utility analysis (CUA) compares costs to quality-adjusted life years, which blend quantity and quality of life. CUA is a specialized form of CEA suited to broad resource allocation; CEA is better for disease-specific decisions.
- CEA measures outcomes in natural units specific to a condition, such as cases prevented or life years gained, while CUA converts all outcomes to a single generic metric: quality-adjusted life years.
- A QALY combines length of life with quality of life by multiplying utility value by duration, anchoring perfect health at 1.0 and death at 0.
- CUA allows comparison across unrelated diseases and programs because QALYs are disease-agnostic, whereas CEA is typically confined to within-disease comparisons.
- NICE uses CUA and applies a willingness-to-pay threshold of £20,000 to £30,000 per QALY gained to decide which technologies to fund in the NHS.
- The choice between methods depends on the policy question: use CEA when disease-specific outcomes matter most, and CUA when you must allocate resources across competing programs.
Health economists and policymakers often encounter both cost-effectiveness analysis and cost-utility analysis when evaluating whether a new treatment, drug, or program justifies its cost. The two methods sound similar and are sometimes used interchangeably in conversation, but they measure fundamentally different things and answer different questions. Understanding the distinction is essential for anyone reading health economic literature, commissioning research, or interpreting the evidence that shapes healthcare decisions.
The core difference lies in how each method quantifies health gain. Cost-effectiveness analysis compares costs to outcomes measured in natural units specific to the condition being treated. Cost-utility analysis, by contrast, converts all health outcomes into a single universal metric that allows comparison across diseases and programs. This structural difference makes each method suited to different policy contexts and different kinds of decisions.
Why cost-effectiveness and cost-utility analysis exist as separate methods
Healthcare systems face two distinct types of resource allocation problems, and each requires a different analytical lens. The first is tactical: within a disease or clinical area, does a new intervention offer better value than the current standard? The second is strategic: when resources are limited, how should a health system distribute funding across cancer programs, mental health services, infectious disease control, and dozens of other competing areas?
Cost-effectiveness analysis evolved to answer the first question. It compares an intervention to another intervention or the status quo by estimating how much it costs to gain a unit of health outcome specific to that condition. The metric stays close to the clinical reality: lives saved, cases prevented, symptom-free days gained.
Cost-utility analysis emerged from the recognition that a single metric was needed to compare across these disparate programs. By converting all health outcomes into a common currency, quality-adjusted life years, CUA allows a health system to weigh a cancer drug against a cardiovascular program against a mental health intervention on the same scale. This capability makes CUA particularly valuable for broad healthcare resource allocation decisions.
What cost-effectiveness analysis measures
Cost-effectiveness analysis is a form of economic analysis that compares the relative costs and outcomes of different courses of action. The method answers a straightforward question: for every unit of health gain, how much does it cost? The result is typically expressed as an incremental cost-effectiveness ratio (ICER), calculated as the incremental change in costs divided by the incremental change in health outcome. This ratio tells a decision-maker whether an innovation represents good value relative to the status quo or to competing alternatives.
The outcome metric in cost-effectiveness analysis
The defining feature of CEA is that it measures health gain in natural units specific to the condition being evaluated. For a vaccination program, the outcome might be cases prevented. For a cancer drug, it might be life years gained. For a treatment that reduces hospital readmissions, the outcome might be readmissions avoided. These are concrete, clinically meaningful measures that stakeholders in that disease area understand intuitively.
The choice of outcome metric depends on what matters most for the clinical question. A stroke prevention program might measure outcomes as strokes prevented. A diabetes intervention might measure outcomes as cases of end-stage renal disease prevented, or life years gained, or both. The analyst selects the metric that best captures the intervention's primary benefit.
What CEA does not measure
Cost-effectiveness analysis does not attempt to weigh the quality of life against the quantity of life. If an intervention extends survival by one year but leaves the patient in severe pain or cognitive decline, CEA will record one life year gained. It will not discount that year because quality of life is compromised. CEA also does not provide a common metric for comparing across diseases. A cost per life year in cancer cannot be directly compared to a cost per case prevented in infectious disease, because the units are different. These limitations are not flaws; they are boundaries. CEA excels at answering disease-specific questions. When the policy question crosses disease boundaries, a different method is needed.
What cost-utility analysis measures
Cost-utility analysis is a specific type of cost-effectiveness analysis where the outcome is measured in terms of preference-based valuations of health, most commonly quality-adjusted life years. CUA compares two or more alternative interventions by estimating the incremental cost per QALY gained. The method is designed to solve the cross-disease comparison problem by converting all health outcomes, whether they involve survival, symptom relief, mobility, or cognitive function, into a single index.
Quality-adjusted life years and preference-based outcomes
A quality-adjusted life year is a measure of the value of health outcomes that combines the value of length of life and quality of life into a single index number. One QALY equates to one year in perfect health. Health-related quality of life is characterized by a utility value ranging from 0 (death) to 1 (perfect health).
The QALY calculation is straightforward in principle: the change in utility value induced by the treatment is multiplied by the duration of the treatment effect to provide the number of QALYs gained. Suppose an intervention improves a patient's health-related quality of life from 0.6 to 0.8 (a gain of 0.2 in utility) and sustains that improvement for 5 years. The intervention generates 1 QALY (0.2 times 5 years).
The utility values themselves come from preference-based elicitation techniques. These are structured surveys in which respondents express their preferences about different health states. One such technique is the time trade-off method, which anchors a health state on a scale where 1.0 represents full health and 0 represents death. Multi-attribute utility instruments such as the EuroQol five-dimension (EQ-5D), Short-Form 6-Dimension (SF-6D), and Health Utilities Index (HUI) are standardized tools that measure quality of life across multiple dimensions and convert responses into utility scores. NICE specifies that the EQ-5D is the preferred measure of health-related quality of life in adults.
What CUA does not measure
Cost-utility analysis does not capture outcomes that do not translate readily into quality-of-life improvements or life extension. An intervention that reduces anxiety but does not change survival or functional capacity will show a QALY gain only if the utility instruments used detect the anxiety reduction. If they do not, the benefit is invisible to the analysis. CUA also does not measure financial burden on patients or families, productivity gains, or broader social benefits. These fall outside the scope of health utility measurement. Like CEA, CUA is not a complete accounting of all value; it is a focused tool designed to answer a specific question about health-related resource allocation.
How the two methods differ on key criteria
The two methods differ systematically across several dimensions that determine which is appropriate for a given decision.
The table shows that CEA and CUA are not competing methods but complementary ones, each optimized for a different scope of decision. CEA is narrower and more specific; CUA is broader and more generic.
When each method is the appropriate choice
The choice between CEA and CUA depends on the scope and nature of the policy question being asked. If a decision-maker needs to evaluate whether a new cancer drug offers better value than the current standard treatment, CEA is appropriate. The question is disease-specific, stakeholders care about cancer-specific outcomes like survival or progression-free survival, and a natural-unit metric is clinically meaningful. CEA will produce a cost per life year or cost per progression-free year that oncologists and cancer programs can interpret directly.
If a health system must allocate a fixed budget across multiple programs, oncology, cardiology, mental health, infectious disease, CUA is the better tool. Because all programs are converted to cost per QALY, the system can compare them on a common scale and make trade-offs explicitly. A payer using CUA can ask: "Is this cancer drug worth £25,000 per QALY when a mental health intervention costs £15,000 per QALY?" The question requires a common metric, which only CUA provides.
Within a single disease area, CEA may be preferred even when CUA is technically feasible. Clinicians and patients often find disease-specific outcomes more intuitive and relevant than QALYs. A cardiovascular program director understands "cost per heart attack prevented" more readily than "cost per QALY." If the decision is internal to that program, CEA's specificity is an advantage, not a limitation.
CUA becomes essential when the decision crosses program or disease boundaries, when quality of life is a major component of the intervention's benefit, or when the decision-maker explicitly wants to compare health gains across different clinical areas.
How payers and regulators use these analyses differently
Health technology assessment bodies, the organizations that decide which drugs, devices, and interventions a health system will fund, frequently require CUA as part of their decision-making process. The purpose of health technology assessment is to provide policymakers with evidence to inform decision-making and develop guidance on the reimbursement and administration of new health technologies in a national healthcare system.
NICE, the health technology assessment body in England, exemplifies this approach. CUA studies are routinely used in the UK to inform resource allocation decisions across different healthcare settings and help inform decisions made by NICE about which drugs and medical devices to provide in the English NHS. NICE currently assesses value for money for the NHS by applying a cost-effectiveness range of £20,000 to £30,000 per QALY gained, with new thresholds of £25,000 to £35,000 per QALY to be applied from April 2026 onwards. These thresholds represent a willingness-to-pay: if an intervention costs less than the threshold per QALY gained, it is generally considered to offer good value.
Cost-utility analysis is useful for decision-makers who need to allocate scarce resources among competing health programs or technologies. The QALY-based approach enables NICE and similar bodies to make consistent, comparable decisions across their entire portfolio. An intervention that costs £22,000 per QALY can be evaluated against the same threshold whether it treats cancer, heart disease, or mental illness.
Cost-effectiveness analysis plays a different role in this ecosystem. Considerable resources have been devoted to the study of the cost-effectiveness of new cancer drugs as a basis for decisions about payment and use. Within specialized domains like oncology, disease-specific CEA analyses often accompany or precede CUA studies. These provide additional context and allow decision-makers to see how an intervention performs on outcomes that matter most to patients and clinicians in that field. A cancer drug submission to NICE might include both a CEA (cost per life year gained) and a CUA (cost per QALY gained), giving the appraisal committee a richer picture of the intervention's value.
Do this automatically
Analysts performing cost-effectiveness analysis must manually extract disease-specific outcome data from clinical trials, calculate incremental cost-effectiveness ratios for each intervention variant, and repeat this process across multiple comparisons, a workflow that multiplies in complexity when evaluating cost-utility analysis alongside it using preference-weighted metrics like QALYs. Software platforms can automate the data extraction, ratio calculations, and comparative modeling that these parallel analytical methods require, reducing the time spent on arithmetic and cross-referencing. Healthcare research runs this kind of analysis end to end and cites every figure back to its original source, across as many subjects as you need, with Mimir attaching a citation to every figure. It will not predict a trial's outcome or advise on anyone's treatment. Those decisions stay with clinicians and regulators, and deliberately so. Every plan includes it, including the free one.
Start your first report and run it on something you already know well.
This article is general information about healthcare and life-sciences topics. It is not medical advice, diagnosis, or treatment guidance, and it is not a substitute for a qualified professional. Any treatment decision should be discussed with a clinician.
